Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer

作者：Leslie M. Randall, Yang Xiang, Takashi Matsumoto, Diana Giannarelli, Dency Pilar Milla, Karla Alejandra Lopez, Alejandro Acevedo, Júlia Vízkeleti, Ritu Salani, Angélica Nogueira‐Rodrigues, Fernando Contreras Mejía, Jacob Korach, Hüseyin Akıllı, Jung‐Yun Lee, Valeriya Saevets, Vanessa Samouëlian, Jalid Sehouli, Ekkasit Tharavichikul, Vladyslav Sukhin, Nicoletta Colombo, Chih‐Long Chang, Juan Cueva, Susan Lalondrelle, Edgar Petru, Elizabeth A. Szamreta, Allison Martin Nguyen, Karin Yamada, Kan Li, Sandro Pignata, Domenica Lorusso · 发表于：Gynecologic Oncology · 年份：2025 · DOI：10.1016/j.ygyno.2025.06.003 · 被引用次数：7 · 研究领域：Endometrial and Cervical Cancer Treatments、Cancer Immunotherapy and Biomarkers、Colorectal and Anal Carcinomas